Research clearly suggests that there are proven ways of developing one's leadership potential and capacity, but it takes hard ...
Alector faces a strategic reset after GSK’s termination of their neuroscience collaboration, shifting the investment case to ...
Jared Holz, health care sector strategist at Mizuho Securities, joins 'Squawk on the Street' to discuss GSK’s plan to acquire Nuvalent for $10.6 billion, his view on Eli Lilly, and more. Got a ...
GSK GSK4.25%increase; up pointing triangle agreed to buy U.S. cancer-drug developer Nuvalent NUVL 0.03%increase; up pointing triangle for $10.6 billion, the British pharmaceutical company’s latest ...
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — GSK said Tuesday it would ...
Jared Holz, health care sector strategist at Mizuho Securities, joins 'Squawk on the Street' to discuss GSK’s plan to acquire Nuvalent for $10.6 billion, his view on Eli Lilly, and more. MAGA melts ...
GSK (GSK) is preparing a high-stakes push into oncology, lining up five late-stage trials at once for a promising cancer drug as new CEO Luke Miels seeks to reshape the company’s historically cautious ...
GSK’s planned investment of up to $800 million in its campus near Marietta got a $9 million boost from a state Redevelopment Capital Assistance Program grant earlier this year. The grant is part of ...
GSK struck a $950 million deal to buy Canada’s 35Pharma, a biopharmaceutical company developing cardiopulmonary treatments, as the U.K. drugmaker seeks to bolster its exposure to diseases linked to ...
Acquisition includes HS235, a potentially best-in-class activin signalling inhibitor in clinical development for treatment of cardiopulmonary diseases HS235 offers potential to treat pulmonary ...
GSK Plc’s new chief executive officer plans to speed up research and development and look for acquisitions as the British drugmaker tries to convince investors it can offset a looming patent cliff.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results